Team Building in the White Mountains

July 27, 2021 - Biocytogen Boston Corporation held a team-building retreat at the Grand View Mountain Resort in New Hampshire last week. The event, propelled…

Read more
Biocytogen/Eucure Biopharma’s CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA

BOSTON and BEIJING, July 6, 2021 --Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing antibody drugs with independent intellectual property rights, announced…

Read more
Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars

BEIJING and BOSTON, June 22, 2021- Biocytogen, an international biotechnology company focused on antibody drug research and development using innovative genetically engineered animal models, today…

Read more
Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting

BEIJING and BOSTON, June 1, 2021 /PRNewswire/ -- Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual…

Read more
Biocytogen Best Research Paper Award commends typhoid toxin and potential peptide therapy research

Boston, May 27, 2021, adapted from Cornell Chronicle, Graduate students and postdoctoral researchers in the Department of Microbiology and Immunology from Cornell University faced stiff…

Read more
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences’ Anti-PD-1

BOSTON and BEIJING, March 22, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi…

Read more
Biocytogen announces acquisition of a third Beacon Optofluidic system

BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument,…

Read more
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences’ Toripalimab

BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with…

Read more
Biocytogen and LiberoThera Enter into Strategic Collaboration Agreement

Beijing, China and Tokyo, Japan, February 1st, 2021 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and LiberoThera Co.,Ltd (“LiberoThera”) announced today that they have entered into…

Read more
Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China

BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial in China to evaluate the safety, tolerability,…

Read more
Back to top